Article thumbnail

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts

By Hichame Id Boufker, Laurence Lagneaux, Mehdi Najar, Martine Piccart, Ghanem Ghanem, Jean-Jacques Body and Fabrice Journé
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). A: Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem
  2. (1991). A: Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell
  3. (2005). Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res
  4. Adhesion to Vitronectin and Collagen I Promotes Osteogenic Differentiation of Human Mesenchymal Stem Cells.
  5. (1998). Advances in the osteoblast lineage.
  6. (2004). Bone marrow-derived mesenchymal stem cells already express specific neural proteins before any differentiation. Differentiation
  7. (2006). Bone-related gene profiles in developing calvaria. Gene
  8. (1997). Brugge JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol
  9. (2002). Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis.
  10. (1999). Chronic myeloid leukemia.
  11. (2001). CM: Purification ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood
  12. (2008). CV: Modulation of Src activity by low molecular weight protein tyrosine phosphatase during osteoblast differentiation. Cell Physiol Biochem
  13. (2005). Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res
  14. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. British journal of cancer 2009, 101:263-268.Id Boufker et al.
  15. (2000). de los Santos K, et al.: Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nature genetics
  16. (2000). Decreased c-Src expression enhances osteoblast differentiation and bone formation.
  17. (2003). Delloye C: Bone-likex nodules formed by human bone marrow stromal cells: comparative study and characterization.
  18. (2009). Dibb NJ: Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia
  19. (2005). Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials
  20. (2006). Estrogen receptor alpha genotype confers interindividual variability of response to estrogen and testosterone in mesenchymal-stem-cell-derived osteoblasts.
  21. (2009). et al.: Effects of imatinib mesylate in osteoblastogenesis. Experimental hematology
  22. (2005). et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res
  23. (2000). Fernande MH: Human bone cell cultures in biocompatibility testing. Part I: osteoblastic differentiation of serially passaged human bone marrow cells cultured in alpha-MEM and in DMEM. Biomaterials
  24. (2010). Finkenzeller G: Platelet-derived growth factor receptor signaling is not involved in osteogenic differentiation of human mesenchymal stem cells. Tissue engineering
  25. (2004). HT: The role of BMP-6, IL-6, and BMP-4 in mesenchymal stem cell-dependent bone development: effects on osteoblastic differentiation induced by parathyroid hormone and vitamin D(3). Stem Cells Dev
  26. (2007). Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res
  27. (2007). Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell proliferation
  28. (2006). Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
  29. (2004). Jr: Src protein-tyrosine kinase structure and regulation.
  30. (2003). Khosla S: Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res
  31. (2008). Long-term imatinib therapy promotes bone formation in CML patients. Blood
  32. (2004). Mesenchymal stem cells: harnessing cell plasticity to tissue and organ repair. Blood Cells Mol Dis
  33. (2005). Mesenchymal stem cells. Ann Med
  34. (2008). Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med
  35. (1997). Muschler GF: Characterization of human bone marrow stromal cells with respect to osteoblastic differentiation.
  36. (1983). Osteoblasts isolated from mouse calvaria initiate matrix mineralization in culture.
  37. (2004). Oxysterols regulate differentiation of mesenchymal stem cells: pro-bone and anti-fat. J Bone Miner Res
  38. (2003). Parathyroid hormone-related peptide interacts with bone morphogenetic protein 2 to increase osteoblastogenesis and decrease adipogenesis in pluripotent C3H10T 1/2 mesenchymal cells. Endocrinology
  39. (2006). Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Molecular pharmacology
  40. (1998). RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.
  41. (2003). RANKL expression is related to the differentiation state of human osteoblasts.
  42. Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases.
  43. (1997). SP: Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro.
  44. (2009). Src as a therapeutic target in men with prostate cancer and bone metastases. BJU international
  45. (2010). Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene
  46. (2006). SRC inhibitors in metastatic bone disease. Clin Cancer Res
  47. (2008). Successful vitrification of human amnionderived mesenchymal stem cells. Human reproduction
  48. (2009). The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res
  49. (2009). Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia
  50. (2002). TK: Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Curr Pharm Des
  51. (1999). Transient upregulation of CBFA1 in response to bone morphogenetic protein-2 and transforming growth factor beta1 in C2C12 myogenic cells coincides with suppression of the myogenic phenotype but is not sufficient for osteoblast differentiation.
  52. (2004). Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. Embo J
  53. (2005). Windle JJ: Paget disease of bone.